Suppr超能文献

维生素K环氧化物还原酶复合体亚单位1(VKORC1)基因多态性对华法林维持剂量的影响:对53项研究的一项新的系统评价和荟萃分析

Impact of VKORC1 gene polymorphisms on warfarin maintenance dosage: A novel systematic review and meta-analysis of 53 studies.

作者信息

Tang Wei, Shi Qing-Ping, Ding Feng, Yu Mei-Ling, Hua Jian, Wang Yong-Xin

出版信息

Int J Clin Pharmacol Ther. 2017 Apr;55(4):304-321. doi: 10.5414/CP202833.

Abstract

OBJECTIVE

To analyze the correlation between gene polymorphisms and warfarin maintenance dosage, as well as the correlation of dosage of warfarin with age and ethnicity.

METHODS

We retrieved related studies published between January 2000 and March 2016 from PubMed, Embase, the Cochrane Library, Web of Science, VIP, CNKI, and Wan Fang data. Two reviewers independently screened literature according to the inclusion and exclusion criteria, extracted data and crosscheck data. Then, RevMan5.3 software was used to perform a meta-analysis.

RESULTS

53 studies were included in the meta-analysis. The most prevalent genotypes were -1639 AA, 1173 TT, and 3730 GG in both Asian and Caucasians, but the distribution frequencies of all three were higher in Asians than in Caucasians. The meta-analysis showed that compared with homozygous -1639 AA carriers, carriers of type GA, GG, and G (GA + GG) required 45% (95% confidence interval (CI) 42 - 49), 77% (95% CI 70 - 84), and 51% (95% CI 47 - 55) higher warfarin doses, respectively. Carriers of type CC, TC, and C (CC + TC) required 83% (95% CI 73 - 92), 26% (95% CI 23 - 29), and 53% (95% CI 44 - 62) higher warfarin doses, respectively, compared to homozygous 1173 TT carriers. Carriers of type AA, GA, and A (AA + GA) required 40% (95% CI 29 - 51), 25% (95% CI 17 - 33), and 33% (95% CI 21 - 45) higher warfarin doses, respectively, compared to carriers of the homozygous 3730 GG polymorphism (all p < 0.05). Subgroup analysis showed that Asian patients aged ≤ 60 years carrying 1173 CC, TC, and C genotypes required 28%, 39%, and 22% higher warfarin doses, respectively, compared with patients aged > 60 years. Caucasian patients aged > 60 years carrying -1639 GA, GG and G genotypes needed 24%, 39%, and 37% lower warfarin doses, respectively, compared with patients aged ≤ 60 years. These differences were statistically significant (p < 0.05).

CONCLUSIONS: Our study showed that the relationship between VKORC1 gene polymorphisms and warfarin maintenance dose differs between individuals, and that individuals with different ages and ethnicities require different doses of warfarin. Caucasians carriers of genotype -1639 GG, G and 1173 CC, TC, C required a higher mean daily warfarin doses compared with Asian patients. Therefore, in order to achieve optimal treatment and lowest risk, gene polymorphism detection is suggested.
.

摘要

目的

分析基因多态性与华法林维持剂量之间的相关性,以及华法林剂量与年龄和种族的相关性。

方法

我们从PubMed、Embase、Cochrane图书馆、Web of Science、维普、中国知网和万方数据中检索了2000年1月至2016年3月发表的相关研究。两名评价员根据纳入和排除标准独立筛选文献,提取数据并交叉核对数据。然后,使用RevMan5.3软件进行荟萃分析。

结果

荟萃分析纳入了53项研究。在亚洲人和白种人中,最常见的基因型分别为-1639 AA、1173 TT和3730 GG,但这三种基因型在亚洲人中的分布频率均高于白种人。荟萃分析表明,与纯合-1639 AA携带者相比,GA型、GG型和G型(GA + GG)携带者所需的华法林剂量分别高45%(95%置信区间(CI)42 - 49)、77%(95% CI 70 - 84)和51%(95% CI 47 - 55)。与纯合1173 TT携带者相比,CC型、TC型和C型(CC + TC)携带者所需的华法林剂量分别高83%(95% CI 73 - 92)、26%(95% CI 23 - 29)和53%(95% CI 44 - 62)。与纯合3730 GG多态性携带者相比,AA型、GA型和A型(AA + GA)携带者所需的华法林剂量分别高40%(95% CI 29 - 51)、25%(95% CI 17 - 33)和33%(95% CI 21 - 45)(所有p < 0.05)。亚组分析表明,年龄≤6岁且携带1173 CC、TC和C基因型的亚洲患者,与年龄>60岁的患者相比,所需的华法林剂量分别高28%、39%和22%。年龄>60岁且携带-1639 GA、GG和G基因型的白种人患者,与年龄≤60岁的患者相比,所需的华法林剂量分别低24%、39%和37%。这些差异具有统计学意义(p < 0.05)。

结论

我们的研究表明,不同个体中VKORC1基因多态性与华法林维持剂量之间的关系不同,不同年龄和种族的个体所需的华法林剂量不同。与亚洲患者相比,基因型为-1639 GG、G和1173 CC、TC、C的白种人携带者平均每日所需的华法林剂量更高。因此,为了实现最佳治疗和最低风险,建议进行基因多态性检测。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验